Paul M Barr

37PUBLICATIONS
162CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)OtorhinolaryngologyHaematological tumoursMolecular targetsCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Nov 21, 2025
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

Jeff P Sharman, Bin Liu, Denise Y Wang

|Jul 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|Jan 02, 2025
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Jennifer E Bruno, Christine A Herne, Andrea M Baran

|Dec 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown

|Aug 22, 2024
Ready, AIM, stop: ibrutinib plus venetoclax in MCL.

Danielle S Wallace, Paul M Barr

Pageof 7

Frequent Collaborators

8 joint publications

John N Allan

6 joint publications

Paolo Ghia

5 joint publications

Clive S Zent

4 joint publications

Harry Erba